We report a retrospective analysis of patients admitted to a tertiary intensive care unit who received recombinant activated factor VIIa (rFVIIa) 
Massive haemorrhage and its consequences remain a significant cause of morbidity and mortality in critically ill patients. Conventional therapy focuses on surgical control of bleeding, preservation of normothermia, and fluid resuscitation including the transfusion of red blood cells, clotting factors and platelets. Despite optimal conventional management, patients may develop the triad of acidosis, hypothermia and coagulopathy, and bleeding in this situation can be impossible to control. Treatments that aid early control of bleeding and help prevent this triad have therapeutic potential.
Recombinant factor VIIa (rFVIIa) has been licensed for use in haemophiliacs with inhibitors to exogenous factor VIII or IX concentrates, and has been extensively used with few adverse events in this population. Endogenous Factor VIIa binds to tissue factor expressed at the site of injury and has a central role in the initiation and amplification of the coagulation cascade, initially by activating Factors X and IX. This results in a large thrombin "burst" which catalyses and stabilizes fibrin clots at the site of injury. There have been recent anecdotal reports of beneficial effects from the use of rFVIIa in patients with previously normal coagulation but massive haemorrhage and coagulopathy unresponsive to conventional therapy. We have also used rFVIIa in these circumstances and this report documents our experience with three patients following cardiac surgery, three patients with multiple blunt trauma, a patient with a close range shotgun wound to the abdomen, a patient with a ruptured iliac artery aneurysm, and a patient with acute fatty liver of pregnancy who experienced haemorrhage after caesarean section.
MATERIALS AND METHODS
Liverpool Hospital is a tertiary referral hospital and major trauma service for the population of Sydney South West Area Heath Service (SSWAHS), *B.M., B.S., B.Med.Sci., M.R.C.P., Registrar. †M.B., B.S., F.R.C.P., F.R.C.A., F.A.N.Z.C.A., F.J.F.I.C.M., Staff Specialist. and a teaching hospital of the University of New South Wales. The intensive care unit (ICU) is a Level III facility equipped to manage 25 adult high dependency and intensive care patients. The ICU deals with all major adult specialties excluding transplantation services.
The study was approved by the then SWSAHS Research Ethics Committee. A retrospective review of pharmacy records was performed to identify patients who received rFVIIa and who were admitted to ICU during the study period from February 2002 to September 2003. Case notes and computerized laboratory data were then reviewed. Data were extracted on the demographics, histories, haematological and biochemical data and the requirement for transfusion of blood products. The coagulopathy and transfusion requirements were compared for the period before and after the administration of rFVIIa and information on eventual patient outcome and complications, in particular of a thromboembolic nature, were specifically sought. Summary statistics are expressed as medians and ranges. Statistical analysis was performed using Stata version 7 and as data was not normally distributed the difference in PT and APTT values pre and post rFVIIa administration was analysed using Wilcoxon signed-rank test which provided a two-tailed P value.
RESULTS
Nine patients were identified as having received rFVIIa and being admitted to the ICU. All nine patients had developed a coagulopathy that was unresponsive to conventional therapy, and all patients were thought to be in imminent risk of dying from continued haemorrhage. Four patients were the victims of trauma (three blunt, one penetrating), three patients were post cardiac surgery, one patient had a ruptured iliac artery aneurysm and one patient had acute fatty liver of pregnancy and was bleeding after an emergency caesarean section. rFVIIa was administered following discussions between the ICU specialist, anaesthetists, haematologists and surgeons. A short summary of each case and outcome is given in Table 1 , clinical data are given in Table 2 . The median age was 42 years (range 17-80) and two patients were female. At the time of administration of rFVIIa the patients had biochemical and haematological markers of haemorrhagic shock and coagulopathy. The median pH was 7.26 (7.08-7.36) reflecting metabolic acidosis (median standardized base excess -8 (-14 to -3)). Severe hypothermia was unusual (median temperature 36.4°C (34.9-37.2)) reflecting our abilities to maintain body temperature despite massive fluid infusion. Coagulation studies were available a median 120 minutes (range 20-300) before rFVIIa administration and a median 80 minutes (range 30-330) after administration. Coagulopathy was demonstrated by a median PT of 17 seconds (14. 6 (platelet count <150×10 9 /l) was common (median 78×10 9 /l (49-279). Seven of the nine patients had a platelet count of <100×10 9 /l but none had a platelet count <40×10 9 /l. Eight of the nine patients received a massive transfusion, receiving a median of 19 (4-59) units of red blood cells (RBCs) and 41 (22-97) units of coagulation factors (FFP, cryoprecipitate and platelets) before rFVIIa was given.
The median total dose of rFVIIa given was 7.2 mg (4.8-16.8), two patients received multiple doses. Shortly after administration of rFVIIa six of the nine patients demonstrated a reduction in blood drainage and three of the nine demonstrated the ability to make blood clots where previously this had been absent. All patients showed an improvement in markers of coagulopathy (median reduction in PT immediately post rFVIIa was 39% (32%-51%); P=0.008). The PT was normalized or supra-normalized in seven patients. The APTT improved in seven of the nine cases (median reduction 14% (17%-53%); P=0.05).
There was a marked reduction in the requirement for transfusion post rFVIIa ( Figure 1, Table 2 ). Only one patient required more than 10 further units of RBCs, this patient was subsequently found to be bleeding from an arterial pedicle at re-sternotomy post CABG. Post rFVIIa there was also a marked reduction in the need for transfusion of platelets, FFP and cryoprecipitate (median requirement 4 units (0-48)).
Eight patients survived and seven were discharged from hospital, one patient remains an inpatient after 15 months. One patient died two days after admission due to haemorrhage from a torn subclavian vein which complicated the insertion of a dialysis catheter.
There were no complications directly attributable to rFVIIa administration. One patient, at high risk of venous thromboembolism, developed symptomatic pulmonary embolism seven weeks after the administration of rFVIIa; this patient was discharged home on anticoagulation.
DISCUSSION
Recombinant activated factor VIIa (rFVIIa) is licensed for use in haemophiliacs with inhibitors to exogenous factor VIII or IX concentrates but there are reports of benefit in non-haemophiliac patients with massive haemorrhage and coagulopathy unresponsive to conventional therapy. Since the first description of its use in a trauma patient 1 rFVIIa has been used to control bleeding in a variety of nonhaemophiliac patients who have failed to respond to conventional therapies [2] [3] [4] [5] [6] [7] . Our cumulative experience includes patients who have suffered multiple injuries from road trauma or assault, postoperative cardiac surgical patients and a patient who had major complications of pregnancy. Our experience suggests that rFVIIa may control the bleeding in these cases.
Our case series shows an improvement in clinical evidence of coagulopathy (the amount of blood drainage and the formation of blood clots which were previously absent), laboratory tests of coagulation and decrease in transfusion requirement in the 48 hours following administration of rFVIIa. This was associated with a good outcome in the majority of cases. The patients were refractory to conventional therapy and were thought to be at imminent risk of dying. Our patients exhibited at least two components of the triad of acidosis, hypothermia and coagu-lopathy that occurs with massive haemorrhage and transfusion. With aggressive warming techniques we appear to be able to reduce the incidence of severe hypothermia associated with massive haemorrhage and transfusion. There has been concern that rFVIIa may be less effective when given to profoundly hypothermic and acidotic patients and this may need to be considered when using this expensive resource in this setting. Recent evidence suggests that rFVIIa should be effective in enhancing haemostasis in hypothermic patients. However, because the activity of FVIIa is significantly affected by pH, its efficacy may be reduced in acidotic patients. Consequently it has been suggested that clinicians who use rFVIIa should consider biochemical correction of severe acidosis before administration of rFVIIa 8 . rFVIIA has a good safety profile in the bleeding haemophiliacs. The incidence of serious adverse events associated with its use is less than 1%; however, there remain concerns regarding the agent's potential to induce thrombosis 9, 10 . Information on safety outside this setting is lacking. Given the nature of the mechanism of action of rFVIIA there are concerns of a potential increased risk of thromboembolism, particularly as the patient groups likely to receive it are already at high risk. One multi-trauma patient with major pelvic injuries in our series had confirmed venous thrombo-embolism seven weeks after administration of rFVIIa. A causal relationship cannot be excluded and requires full consideration and evaluation in future studies.
In Australia, rFVlla is marketed as NovoSeven ® (NovoNordisk, Denmark) and is indicated for use in the control of bleeding and surgery (prophylaxis) in patients with inhibitors to coagulation factors Vlll and lX. The true role of rFVIIa in the management of haemorrhage in non-haemphiliac patients has yet to be fully established. Given the availability of rFVIIa and the perceived benefits, institutions are developing local protocols and guidelines for its use. In our institution this has involved multi-disciplinary discussion and production of a massive transfusion guideline document to assist clinicians.
Our current guidelines state that if conventional therapy has failed to control the blood loss (usually at least 10 units of RBCs, 10 units of FFP, 10 units of platelets, and 10 units of cryoprecipitate will have been given), and bleeding with coagulopathy continues, and all surgical and embolisation procedures have been attempted, and consultation with a haematologist confirms optimal conventional therapy and the appropriate dosage of rVIIa, then a dose of 90 µg/kg rFVIIa may be given. The dose is rounded up or down to the nearest 1.2 mg vial size to avoid any wastage. Clinical response is usually obvious within 20 minutes. If there is no response within 20 minutes, a second dose of 90 µg/kg rFVIIa may be considered.
More data on efficacy, safety, optimal dosage, and cost-effectiveness of rFVIIa are required. The cost of rFVIIA is substantial. The cost of treating the patients in our series ranged from $6,300-$15,330. This cost may however be mitigated by the reduced cost resulting from reduced blood products usage, particularly as we move towards a user-pays system for blood products under the new National Blood Authority, and potential savings associated with a reduction in morbidity, mortality and length of stay.
Randomized controlled trials in Australia and other countries are focusing on numerous areas including the use of rFVlla in paediatric cardiothoracic surgery, intracerebral haemorrhage, liver transplantation, liver surgery and bone marrow transplantation 10 .
